{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:44:29Z","timestamp":1767152669776,"version":"build-2238731810"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/nrdp.2018.13","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T09:17:03Z","timestamp":1519204623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Authors' reply: Paraneoplastic autoimmune multiorgan syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology"],"prefix":"10.1038","volume":"4","author":[{"given":"Aimee S.","family":"Payne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kasperkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph T.","family":"Ellebrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"BFnrdp201813_CR1","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz, M. et al. Pemphigus. Nat. Rev. Dis. Primers 3, 17026 (2017).","DOI":"10.1038\/nrdp.2017.26"},{"key":"BFnrdp201813_CR2","doi-asserted-by":"publisher","first-page":"18012","DOI":"10.1038\/nrdp.2018.12","volume":"4","author":"Kyle T. Amber","year":"2018","unstructured":"Amber, K. T. Paraneoplastic autoimmune multi-organ syndrome is a distinct entity from traditional pemphigus subtypes. Nat. Rev. Dis. Primershttps:\/\/doi.org\/10.1038\/nrdp.2018.12 (2018).","journal-title":"Nature Reviews Disease Primers"},{"key":"BFnrdp201813_CR3","first-page":"193","volume":"137","author":"VT Nguyen","year":"2001","unstructured":"Nguyen, V. T. et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch. Dermatol. 137, 193\u2013206 (2001).","journal-title":"Arch. Dermatol."},{"key":"BFnrdp201813_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1172\/JCI3647","volume":"102","author":"M Amagai","year":"1998","unstructured":"Amagai, M., Nishikawa, T., Nousari, H. C., Anhalt, G. J. & Hashimoto, T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J. Clin. Invest. 102, 775\u2013782 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201813_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2011.449","volume":"132","author":"MA Saleh","year":"2012","unstructured":"Saleh, M. A. et al. Pathogenic anti-desmoglein 3 mAbs cloned from a paraneoplastic pemphigus patient by phage display. J. Invest. Dermatol. 132, 1141\u20131148 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrdp201813_CR6","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1038\/ncomms5167","volume":"5","author":"MJ Cho","year":"2014","unstructured":"Cho, M. J. et al. Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nat. Commun. 5, 4167 (2014).","journal-title":"Nat. Commun."},{"key":"BFnrdp201813_CR7","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1172\/JCI57379","volume":"121","author":"H Takahashi","year":"2011","unstructured":"Takahashi, H. et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J. Clin. Invest. 121, 3677\u20133688 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201813_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4049\/jimmunol.1203536","volume":"191","author":"T Hata","year":"2013","unstructured":"Hata, T. et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. J. Immunol. 191, 83\u201390 (2013).","journal-title":"J. Immunol."}],"updated-by":[{"DOI":"10.1038\/nrdp.2018.32","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000}}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrdp201813.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrdp201813","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrdp201813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/nrdp201813.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T19:06:06Z","timestamp":1671563166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrdp201813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,6,7]]}},"alternative-id":["BFnrdp201813"],"URL":"https:\/\/doi.org\/10.1038\/nrdp.2018.13","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"22 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.P. has previously served as a consultant for Syntimmune and TG Therapeutics and receives or has received grants or research support from the US NIH (R01-AR057001, R56-AR064220 and R01-068288), the Dermatology Foundation and Sanofi. She is co-inventor on a patent related to chimeric immunoreceptor therapy of pemphigus. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US NIH. C.T.E. has received grants or research support from Deutsche Forschungsgemeinschaft (EL711\/1-1) and is co-inventor on a patent related to chimeric immunoreceptor therapy of pemphigus. H.T. receives grants from Japan Society for the Promotion of Science. D.Z. is an advisory board member for Roche Pharma, and a consultant for Euroimmun, Almirall, UCB, Fresenius and arGEN-X. He received speakers honoraria and\/or travel\/accommodations\/meeting compensation from Biotest, Fresenius, Miltenyi, Roche Pharma, Biogen Idec, AbbVie, UCB, Janssen and grants or research support from Euroimmun, Miltenyi, Fresenius, Biotest, Dompe, Almirall, Biogen and Roche. He holds the patent Euroimmun: DE 10 2006 059 574 A1. M.A. has received speaker honoraria and grants from Nihon Pharmaceutical, research support from Medical & Biological Laboratories, Health Sciences Research Grants for Research on Rare and Intractable Diseases from Ministry of Health, Labour, and Welfare, and grants from Japan Society for the Promotion of Science and Agency for Medical Research and Development. M.K. and J.Y. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18013"}}